NCT06342986View on ClinicalTrials.gov

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Gynecologic CancerOvarian CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

FT536

FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.

DRUG

Fludarabine

Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.

DRUG

CY

CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.

Trial Locations (1)

55455

RECRUITING

University of Minnesota Masonic Cancer Center, Minneapolis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Masonic Cancer Center, University of Minnesota

OTHER